Interpace terminates rights offering due to adverse CMS policy change for thyroid tests

INTERPACE BIOSCIENCES, INC.

Terminated rights offering and standby purchase agreement with 3K Limited Partnership effective January 28, 2022.
CMS issued new billing policy: no longer reimburses ThyGeNEXT and ThyraMIR tests when billed together for same beneficiary on same date.
Company evaluating potential financial impact and preparing an appeal; seeking alternative financing sources.
CEO stated rights offering termination driven by likely adverse impact of CMS policy change.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.